Great comparison and Well thought out post @sapporo.I am watcher...

Great comparison and Well thought out post @sapporo.

I am watcher of IRX & holder or IHL, so please take this with a pinch of salt due to my biases. Below are just my observations/ thoughts and not criticism.

IHL has many irons in the fire and all are multi-billion $ opportunities and mostly unmet needs. So even if one of the drugs were to get the FDA seal of approval, IHL stands to make at least a billion dollar in sales if they directly sold it, or 10-15% in royalties if licensed to a big pharma player.

I think IRX has huge potential to be the delivery mechanism for a wide variety of CBD drugs and so has a huge potential if they can achieve FDA approval. Still, will this be the only product or will the company develop many more? What happens if there a competitor with a differentiated product that also gains market share? What are multiple irons that the company is going to bring to the table? These are questions to ponder.

I like IRX’s mission, vision, mgmt team, low SOI, skin in the game and backing by Cannvalate, engagement of Camargo etc.,. I will continue to watch and may join the register in due course. GLTAH.